Adding axelopran to immunotherapy for head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests whether adding a new drug called axelopran (which targets a certain opioid receptor) can make the immunotherapy drug pembrolizumab work better against head and neck cancer. You would receive both axelopran and pembrolizumab, with the goal of improving your cancer control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and able to give informed consent.
- You have a type of head and neck cancer called squamous cell carcinoma that cannot be cured by local treatment and has either spread or come back.
- You are planning to receive the immunotherapy drug pembrolizumab (Keytruda) as your first treatment for this cancer, or after platinum chemotherapy didn't work.
- Your cancer tests positive for a marker called PD-L1 (CPS > 1).
- You are taking or willing to start opioid pain medication (like morphine or oxycodone) for cancer pain.
- You have not had immunotherapy for your recurrent/metastatic cancer before (unless it was over a year ago as part of curative treatment).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to give chemotherapy (pulsed doses) together with pembrolizumab (an immunotherapy) for people with head and neck cancer that has come back or spread and cannot be cured with local treatments. The goal is to see if this combination works better than standard approaches.
This trial tests whether adding a drug called ruxolitinib (which helps reduce inflammation) to the standard immunotherapy drug pembrolizumab is safe and effective for people with advanced head and neck cancer. It may help the immunotherapy work better, especially if you have a certain blood marker that suggests high inflammation.
This trial tests whether adding pembrolizumab (an immunotherapy drug) to standard chemotherapy before surgery can help people with advanced head and neck cancer. It aims to see if the combination is more effective than chemotherapy alone.
This Phase 2 study tests pembrolizumab (an immunotherapy medicine) together with induction chemotherapy before the main cancer treatment for stage III/IVA head and neck squamous cell cancer. It aims to improve how well the tumor responds and how long people can stay controlled.
This trial tests a combination of two chemotherapy drugs (carboplatin and paclitaxel) plus a targeted therapy (cetuximab) for people with advanced head and neck cancer that has gotten worse after treatment with pembrolizumab (with or without initial chemotherapy). The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
This trial tests whether adding cetuximab to the standard drug pembrolizumab works better for head and neck cancer that has spread or come back after treatment. It is for people whose cancer did not respond to platinum chemotherapy and whose tumors have a certain immune marker (PD-L1).
Hear when a new Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.